3-Hydroxymorphinan
 | |
|---|---|
| Systematic (IUPAC) name | |
| (±)-morphinan-3-ol | |
| Clinical data | |
| Legal status | ? |
| Pharmacokinetic data | |
| Bioavailability | 18% |
| Identifiers | |
| CAS number | 1531-12-0  |
| ATC code | None |
| ChemSpider | 16735936  |
| Chemical data | |
| Formula | C16H21NO |
| Mol. mass | 243.344 g/mol |
| |
| |
| (what is this?) (verify) | |
3-Hydroxymorphinan (3-HM), or morphinan-3-ol, is a psychoactive drug of the morphinan family.[1] It is the racemic version of norlevorphanol.
The dextrorotatory stereoisomer of the compound is an active metabolite of dextromethorphan, dextrorphan, and 3-methoxymorphinan,[2] and similarly to them has potent neuroprotective and neurotrophic effects on LTS- and MPTP-treated dopaminergic neurons of the nigrostriatal pathway,[3][4] but notably without producing any neuropsychotoxic side effects (e.g., dissociation or hallucinations) or having any anticonvulsant actions.[5][6] It does not seem to bind to the NMDA receptor,[6] and instead, its neuroprotective properties appear result from inhibition of glutamate release via the suppression of presynaptic voltage-dependent Ca2+ entry and protein kinase C activity.[7] In any case, as such, the compound has been investigated as a potential antiparkinsonian agent. A prodrug, GCC1290K, has been developed on account of 3-HM's poor bioavailability (18%), and a New Drug Application has been approved for it by the United States Food and Drug Administration.[6] It is currently undergoing clinical trials for the treatment of Parkinson's disease.[6]
3-HM's levorotatory stereoisomer, norlevorphanol, in contrast to (+)-3-HM, is an opioid analgesic.[8] It was never marketed as such however, probably due to a combination of the facts that norlevorphanol has low bioavailability and that its potency is diminished compared to its N-methylated analogue levorphanol.[9]
See also
References
- ↑ C. R Ganellin; D. J Triggle; F.. Macdonald (1997). Dictionary of pharmacological agents. CRC Press. p. 1378. ISBN 978-0-412-46630-4. Retrieved 29 November 2011.
- ↑ Jacqz-Aigrain E, Cresteil T (1992). "Cytochrome P450-dependent metabolism of dextromethorphan: fetal and adult studies". Developmental Pharmacology and Therapeutics 18 (3-4): 161–8. PMID 1306804.
- ↑ Zhang W, Qin L, Wang T, et al. (March 2005). "3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity". The FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology 19 (3): 395–7. doi:10.1096/fj.04-1586fje. PMID 15596482.
- ↑ Zhang W, Shin EJ, Wang T, et al. (December 2006). "3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro". The FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology 20 (14): 2496–511. doi:10.1096/fj.06-6006com. PMID 17142799.
- ↑ Shin EJ, Lee PH, Kim HJ, Nabeshima T, Kim HC (January 2008). "Neuropsychotoxicity of abused drugs: potential of dextromethorphan and novel neuroprotective analogs of dextromethorphan with improved safety profiles in terms of abuse and neuroprotective effects". Journal of Pharmacological Sciences 106 (1): 22–7. PMID 18198471.
- ↑ 6.0 6.1 6.2 6.3 Shin EJ, Bach JH, Lee SY, et al. (2011). "Neuropsychotoxic and neuroprotective potentials of dextromethorphan and its analogs". Journal of Pharmacological Sciences 116 (2): 137–48. PMID 21606622.
- ↑ Lin TY, Lu CW, Wang SJ (July 2009). "Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan". Neurochemistry International 54 (8): 526–34. doi:10.1016/j.neuint.2009.02.012. PMID 19428798.
- ↑ Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8.
- ↑ Bentham Science Publishers (April 1995). Current Medicinal Chemistry. Bentham Science Publishers. p. 425. Retrieved 29 November 2011.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||